Investigating how cell-free hemoglobin affects blood vessel function in sepsis
Cell-Free Hemoglobin Induces Endothelial Mitochondrial Oxidative Damage Causing Extracellular DNA Release
This study is looking at how a certain type of hemoglobin in the blood affects blood vessel health during sepsis, which is a serious condition that can harm your organs, and it aims to find ways to help critically ill patients feel better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10991663 on NIH RePORTER |
What this research studies
This research explores the impact of oxidized cell-free hemoglobin on blood vessel function during sepsis, a severe condition that can lead to organ failure. The study focuses on understanding how this hemoglobin damages the endothelial cells lining blood vessels, leading to mitochondrial dysfunction and the release of extracellular mitochondrial DNA. By examining these mechanisms, the research aims to uncover potential therapeutic targets to improve outcomes for critically ill patients. Patients may benefit from insights gained about the role of cell-free hemoglobin in sepsis and its effects on vascular health.
Who could benefit from this research
Good fit: Ideal candidates for this research are critically ill patients diagnosed with sepsis or acute respiratory distress syndrome.
Not a fit: Patients who are not critically ill or do not have sepsis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect blood vessels and improve survival rates in patients with sepsis.
How similar studies have performed: Previous research has indicated that targeting oxidative stress in sepsis may improve patient outcomes, suggesting that this approach could be promising.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Riedmann, Kyle Joseph — Vanderbilt University
- Study coordinator: Riedmann, Kyle Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.